Standard

Лекарственные поражения печени у онкологических пациентов. / Ivashkin, V. T.; Raikhelson, K. L.; Palgova, L. K.; Maevskaya, M. V.; Gerasimova, O. A.; Kondrashina, E. A.; Marchenko, N. V.; Baranovsky, A. Yu.

In: Oncogematologiya, Vol. 15, No. 3, 2020, p. 80-94.

Research output: Contribution to journal › Article › peer-review

Harvard

Ivashkin, VT, Raikhelson, KL, Palgova, LK, Maevskaya, MV, Gerasimova, OA, Kondrashina, EA, Marchenko, NV & Baranovsky, AY 2020, 'Лекарственные поражения печени у онкологических пациентов', Oncogematologiya, vol. 15, no. 3, pp. 80-94. https://doi.org/10.17650/1818-8346-2020-15-3-107-127

APA

Ivashkin, V. T., Raikhelson, K. L., Palgova, L. K., Maevskaya, M. V., Gerasimova, O. A., Kondrashina, E. A., Marchenko, N. V., & Baranovsky, A. Y. (2020). Лекарственные поражения печени у онкологических пациентов. Oncogematologiya, 15(3), 80-94. https://doi.org/10.17650/1818-8346-2020-15-3-107-127

Vancouver

Ivashkin VT, Raikhelson KL, Palgova LK, Maevskaya MV, Gerasimova OA, Kondrashina EA et al. Лекарственные поражения печени у онкологических пациентов. Oncogematologiya. 2020;15(3):80-94. https://doi.org/10.17650/1818-8346-2020-15-3-107-127

Author

Ivashkin, V. T. ; Raikhelson, K. L. ; Palgova, L. K. ; Maevskaya, M. V. ; Gerasimova, O. A. ; Kondrashina, E. A. ; Marchenko, N. V. ; Baranovsky, A. Yu. / Лекарственные поражения печени у онкологических пациентов. In: Oncogematologiya. 2020 ; Vol. 15, No. 3. pp. 80-94.

BibTeX

@article{ed3df96efc254d36a77b0366b43d2941,
title = "Лекарственные поражения печени у онкологических пациентов",
abstract = "This review includes information about epidemiological data, development feature, phenotypes, principles of classification, diagnosis, and prognosis for drug-induced liver injury (DILI). Actual clinical recommendations regarding management of the DILI arising in the chemotherapy of cancer discussed. Drugs that can influence on individual pathogenetic mechanisms of growth and symptoms DILI are considered. Clinical studies for the prophylaxis and treatment of DILI associated with anticancer chemotherapy analyzed in detail. The prevention and treatment regimens for DILI in patients receiving chemotherapy and immunotherapy various localizations of cancer given both in research and in practical recommendations.",
keywords = "Bicyclol, Cancer, Checkpoint inhibitor, Chemotherapy, Drug-induced liver injury, Essential phospholipid, Glucocorticosteroids, Hepatotoxicity, N-acetylcysteine, S-аdenosylmethionine, Bicyclol, Cancer, Checkpoint inhibitor, Chemotherapy, Drug-induced liver injury, Essential phospholipid, Glucocorticosteroids, Hepatotoxicity, N-acetylcysteine, S-аdenosylmethionine",
author = "Ivashkin, {V. T.} and Raikhelson, {K. L.} and Palgova, {L. K.} and Maevskaya, {M. V.} and Gerasimova, {O. A.} and Kondrashina, {E. A.} and Marchenko, {N. V.} and Baranovsky, {A. Yu}",
note = "Publisher Copyright: {\textcopyright} 2020 ABV-Press Publishing House. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
doi = "10.17650/1818-8346-2020-15-3-107-127",
language = "русский",
volume = "15",
pages = "80--94",
journal = "Онкогематология",
issn = "1818-8346",
publisher = "Издательский дом {"}АБВ-пресс{"} ",
number = "3",

}

RIS

TY - JOUR

T1 - Лекарственные поражения печени у онкологических пациентов

AU - Ivashkin, V. T.

AU - Raikhelson, K. L.

AU - Palgova, L. K.

AU - Maevskaya, M. V.

AU - Gerasimova, O. A.

AU - Kondrashina, E. A.

AU - Marchenko, N. V.

AU - Baranovsky, A. Yu

N1 - Publisher Copyright: © 2020 ABV-Press Publishing House. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020

Y1 - 2020

N2 - This review includes information about epidemiological data, development feature, phenotypes, principles of classification, diagnosis, and prognosis for drug-induced liver injury (DILI). Actual clinical recommendations regarding management of the DILI arising in the chemotherapy of cancer discussed. Drugs that can influence on individual pathogenetic mechanisms of growth and symptoms DILI are considered. Clinical studies for the prophylaxis and treatment of DILI associated with anticancer chemotherapy analyzed in detail. The prevention and treatment regimens for DILI in patients receiving chemotherapy and immunotherapy various localizations of cancer given both in research and in practical recommendations.

AB - This review includes information about epidemiological data, development feature, phenotypes, principles of classification, diagnosis, and prognosis for drug-induced liver injury (DILI). Actual clinical recommendations regarding management of the DILI arising in the chemotherapy of cancer discussed. Drugs that can influence on individual pathogenetic mechanisms of growth and symptoms DILI are considered. Clinical studies for the prophylaxis and treatment of DILI associated with anticancer chemotherapy analyzed in detail. The prevention and treatment regimens for DILI in patients receiving chemotherapy and immunotherapy various localizations of cancer given both in research and in practical recommendations.

KW - Bicyclol

KW - Cancer

KW - Checkpoint inhibitor

KW - Chemotherapy

KW - Drug-induced liver injury

KW - Essential phospholipid

KW - Glucocorticosteroids

KW - Hepatotoxicity

KW - N-acetylcysteine

KW - S-аdenosylmethionine

KW - Bicyclol

KW - Cancer

KW - Checkpoint inhibitor

KW - Chemotherapy

KW - Drug-induced liver injury

KW - Essential phospholipid

KW - Glucocorticosteroids

KW - Hepatotoxicity

KW - N-acetylcysteine

KW - S-аdenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=85094157520&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/e5a962e7-b139-314e-9e94-f4c92dc53cbb/

U2 - 10.17650/1818-8346-2020-15-3-107-127

DO - 10.17650/1818-8346-2020-15-3-107-127

M3 - статья

AN - SCOPUS:85094157520

VL - 15

SP - 80

EP - 94

JO - Онкогематология

JF - Онкогематология

SN - 1818-8346

IS - 3

ER -

ID: 70481121